Recital 201, Commission Decision of 12/12/2023 declaring a concentration to be compatible with the co…

In forcesince 12 Dec 2023

The Parties argue that the Transaction does not give rise to any conglomerate

concerns because bundling is not a feature of the markets, and even where hypothetical bundling may occur, the price tends to be negotiated separately.294 In addition, the Parties argue that there will also remain several alternative sources of supply for the products concerned, in particular including competitors such as DSM, IFF, Kerry, Sacco and other distributors (who could theoretically market broad bundles of products were it economically attractive to do so) and from suppliers with a more limited range of products such as Lallemand and AB Enzymes, who have offerings within coagulants and/or cultures.295 In addition, the Parties argue that the Parties’ dairy enzymes customers are sophisticated dairies who commonly multisource.296 5.4.2. General Considerations